TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Botox Injection for Treatment of Vaginismus

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Non-pregnant healthy females aged 20-40 with Lamont level 1-4 primary vaginismus.~2. Willing to practice a reliable method of contraception for the first 4 months after treatment.~3. Able to understand and comply with the requirements of the study and sign Informed Consent.~Exclusion Criteria:~1. Female subjects who are pregnant (positive urine pregnancy test), trying to become pregnant, breast-feeding, or who are of childbearing potential and not practicing a reliable method of birth control.~2. Allergy or sensitivity to any component of the test medication~3. History of poor cooperation, non-compliance with medical treatment, or unreliability.~4. Intact hymen, dyspareunia, secondary vaginismus, vulvodynia, dermatopathology of the vulva or perineum, anal fissure, associated urinary or rectal problems, complex pain disorders of the urogenital diaphragm or pelvic floor including pudendal nerve entrapment, psychiatric illness.~5. Treatment with botulinum toxin of any serotype prior to enrollment in study.~6. Any medical condition that may put the subject at increased risk with exposure to BOTOX including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or any other disorder that might interfere with neuromuscular function.~7. Evidence of alcohol, drug abuse or other relevant neuropsychiatric condition.~8. Infection or skin disorder at an anticipated injection site.~9. Any condition or situation that, in the investigator's opinion, may put the subject at significant risk, confound the study results, or interfere significantly with the subject's participation in the study.~10. Participation in an investigational drug study within 30 days of the Baseline Visit.

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- BOTOX (Type: EXPERIMENTAL): intravaginal Botox injections and progressive dilation under anesthesia to cure vaginismus.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: XprESS Eustachian Tube Dilation Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥18 years old~* Have been diagnosed with symptoms of chronic Eustachian tube dysfunction for no less than 12 months prior to enrollment~* Have an overall ETDQ-7 score ≥3.0~* Have record of failed medical management for Eustachian tube dysfunction~Exclusion Criteria:~* Require concomitant procedures at the time of the study enrollment or procedure~* Have patulous Eustachian tube~* Have ear tubes in place or perforation of the tympanic membrane~* Have evidence of internal carotid artery dehiscence~* Be pregnant at the time of enrollment~* Be currently participating in other drug or device studies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- XprESS (Type: EXPERIMENTAL): Balloon dilation of the Eustachian tube
- Control (Type: OTHER): Continued medical management

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: RATe Control in Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Persistent or permanent atrial fibrillation with ventricular rate \> 80/min at rest and/or \> 100/min average at daytime.~* Male or female, age \> 18.~Exclusion Criteria:~* Hypersensitivity or contraindication to metoprolol, verapamil, diltiazem or carvedilol.~* Coronary heart disease or heart failure~* Systolic blood pressure \< 100 mmHg~* AV-conduction disturbance~* Severe hepatic or renal dysfunction~* Thyrotoxicosis~* Ongoing treatment with Digitalis~* Pregnancy or lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Metoprolol (Type: ACTIVE_COMPARATOR): Treatment with Metoprolol 100 mg x 1 for three weeks
- Diltiazem (Type: ACTIVE_COMPARATOR): Treatment with Diltiazem 360 mg x 1 for three weeks
- Verapamil (Type: ACTIVE_COMPARATOR): Treatment with Verapamil 240 mg x 1 for three weeks
- Carvedilol (Type: ACTIVE_COMPARATOR): Treatment with Carvedilol 25 mg x 1 for three weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic's Disease)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Recurrent longitudinal myelitis (\>3 segments of spinal cord involvement by MRI) with or without recurrent ON (unilateral or bilateral) but with normal brain MRI.~* Patients with recurrent longitudinally extensive myelitis without optic neuritis have an underlying pathology and serology similar to NMO and it is appropriate to consider this a form of NMO10.~* Cerebrospinal fluid required no intrathecal IgG synthesis or oligoclonal bands.~* Age was required to be 18-55 years~* Extended Disability Status Score ≤ 7.~Exclusion Criteria:~* Cardiac risk factors (e.g history of congestive heart failure and left ventricular ejection fraction (LVEF) \< 50%~* Systemic diseases such as lupus, Sjogren's syndrome, anti-phospholipid antibody syndrome, sarcoidosis, rheumatoid arthritis, or vitamin B12 deficiency~* Previous treatment with mitoxantrone or anthracyclines

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dobutamine Versus Placebo for Low Superior Vena Cava Flow in Newborns

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~* Newborn infants born at ≤ 28 weeks of gestational age.~* Newborn infants born at \> 28 weeks of gestational age and ≤ 30 weeks of gestational age with moderate-severe respiratory distress syndrome, defined as the necessity of respiratory support with a mean pressure ≥ 4 cm H2O or FiO2 ≥ 0.3~* Admission at the NICU in the first 6 hours of life~* Inotrope treatment absent~* Inform consent signed~Exclusion criteria~* Early systemic hypotension, defined as a mean arterial pressure (MAP) lower than the gestational age, during at least 60 minutes and maintained after volume infusion~* Major congenital malformation~* Informed consent declined

- Gender: ALL
- Minimum Age: None
- Maximum Age: 12 Hours
- Healthy Volunteers: f

Study Arms:
- Dobutamine (Type: EXPERIMENTAL): Patients with low SVCF in the first 12 hours of life will be randomised to receive dobutamine or placebo.
- Placebo (Type: PLACEBO_COMPARATOR): Patients with low SVCF in the first 12 hours of life will be randomised to receive Dobutamine or Placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Tolerability of Escitalopram and Duloxetine in Outpatients With Major Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The patient suffers from a primary diagnosis of MDD according to DSM-IV-TR criteria (classification code 296.xx; current episode assessed using the MINI)~* The patient has a MADRS total score \>=26 and a CGI-S score \>=4 at the Baseline Visit~Exclusion Criteria:~* Any current psychiatric disorder other than MDD as defined in the DSM-IV TR~* Female patients of childbearing potential who are not using effective contraception~* Use of any psychoactive medication 2 weeks prior to screening and during the study~Other protocol-defined inclusion and exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Escitalopram (Type: EXPERIMENTAL): None
- Duloxetine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Seladelpar (MBX-8025) in Subjects With Primary Biliary Cholangitis (PBC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Must have given written informed consent (signed and dated) and any authorizations required by local law~2. 18 to 75 years old (inclusive)~3. Male or female with a diagnosis of PBC, by at least two of the following criteria:~   * History of AP above ULN for at least six months~  * Positive AMA titers (\>1/40 on immunofluorescence or M2 positive by enzyme linked immunosorbent assay (ELISA) or positive PBC-specific antinuclear antibodies~  * Documented liver biopsy result consistent with PBC~4. On a stable and recommended dose of UDCA for the past twelve months or intolerant to UDCA~5. AP ≥ 1.67 × ULN~6. Females of reproductive potential must use at least one barrier contraceptive and a second effective birth control method during the study and for at least 90 days after the last dose. Male subjects who are sexually active with female partners of reproductive potential must use barrier contraception and their female partners must use a second effective birth control method during the study and for at least 90 days after the last dose~Exclusion Criteria:~1. A medical condition, other than PBC, that in the investigator's opinion would preclude full participation in the study or confound its results (e.g., cancer on active treatment)~2. AST or ALT \> 3 × ULN~3. Total bilirubin \> 2.0 mg/dL~4. Total bilirubin \> ULN AND albumin \< LLN with the exception to subjects with Gilbert's Syndrome. Subjects with Gilbert's syndrome are excluded if Direct Bilirubin \> ULN.~5. Auto-immune hepatitis~6. Primary sclerosing cholangitis~7. Known history of alpha-1-Antitrypsin deficiency~8. Known history of chronic viral hepatitis~9. Creatine kinase above ULN~10. Serum creatinine above ULN~11. For females, pregnancy or breast-feeding~12. Use of colchicine, methotrexate, azathioprine, or systemic steroids in the two months preceding screening~13. Current use of fibrates or simvastatin~14. Current use of obeticholic acid~15. Use of an experimental or unapproved treatment for PBC~16. Use of experimental or unapproved immunosuppressant~17. Adverse event leading to MBX-8025 discontinuation from CymaBay's phase 2 PBC study (CB8025-21528)~18. Any other condition(s) that would compromise the safety of the subject or compromise the quality of the clinical study, as judged by the Investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- MBX-8025 (2 mg) (Type: EXPERIMENTAL): MBX-8025 2 mg capsule once daily
- MBX-8025 (5 mg) (Type: EXPERIMENTAL): MBX-8025 5 mg capsule once daily
- MBX-8025 (10 mg) (Type: EXPERIMENTAL): MBX-8025 10 mg capsule once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized, Double-Blind, Placebo-Controlled Study Of Pregabalin In Patients With Fibromyalgia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ACR criteria for fibromyalgia~* A score of more or equal to 40 mm on the Pain VAS~* An average score more or equal to 4 on 4 daily pain diaries~Exclusion Criteria:~* Patients with other severe pain conditions~* Patients with severe depression~* Patients taking excluded medications~* Patients with suicidality

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Pregabalin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Vildagliptin in Type 2 Diabetes Treated With Sulphonylurea and Metformin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes~* HbA1c ≥ 7%~* Age ≥ 18~Exclusion Criteria:~* Contraindication to Vildagliptin~* Pregnant or breast feeding women~* Type 1 diabetes, gestational diabetes, or diabetes with secondary cause~* Chronic hepatitis B or C (except healthy carrier of HBV)~* Liver disease (AST/ALT \> 3-fold the upper limit of normal)~* Renal failure (Cr \> 2.0)~* Cancer within 5 years~* Not appropriate for oral antidiabetic agent~* Medication which affect glycemic control~* Disease which affect efficacy and safety of drugs~* Other clinical trial within 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Vildagliptin (Type: EXPERIMENTAL): Vildagliptin will be added to uncontrolled diabetic patients with sulphonylurea and metformin
- Sulphonylurea dose-up (Type: ACTIVE_COMPARATOR): Sulphonylurea dose will be increased to uncontrolled diabetic patients with sulphonylurea and metformin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Partial Oral Treatment of Endocarditis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Left-sided endocarditis based on the Duke criteria~* Infected with one of the following microorganisms:~  * Streptococci~ * Enterococcus faecalis~ * Staphylococcus aureus~ * Coagulase-negative staphylococci.~* ≥ 18 years~* At least 10 days of appropriate parenteral antibiotic treatment overall, and at least 1 week of appropriate parenteral treatment after valve surgery~* Afebrile (T \< 38.0) \> 2 days~* Decreasing infection parameters (CRP dropped to less than 25% of peak value or \< 20 mg/l, and white blood cell count \< 15 x 109/l) during antibiotic treatment~* No sign of abscess formation by echocardiography~* Transthoracic and transoesophageal echocardiography performed within 48 hours prior to randomization~Exclusion Criteria:~* Body mass index \> 40~* Concomitant infection requiring intravenous antibiotic therapy~* Inability to give informed consent to participation~* Suspicion of reduced absorption of oral treatment due to abdominal disorder~* Reduced compliance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Guideline treatment with parenteral antibiotics (Type: ACTIVE_COMPARATOR): Guideline treatment with parenteral antibiotics
- Oral treatment with antibiotics (Type: EXPERIMENTAL): Oral treatment with antibiotics based on resistens pattern

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Improving Functions in MTBI Patients With Headache by rTMS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female age between 18 to 50~* History of MTBI based on the clinical diagnostic criteria~* History of headache more than 3 months~* No prior experience of TMS treatment~* Pre-treatment headache intensity M-VAS 30(0-100 scale) and average daily headache NPS 3(0-10 scale)~* At least one headache exacerbation per day~* A normal brain MRI in the past 3 months~Exclusion Criteria:~* Pregnancy~* History of pacemaker implant~* Any ferromagnetic(e.g. bullet fragment, shrapnel, device implant) in the brain or body that will prohibit the patients from having a brain MRI~* History of dementia, major psychiatric diseases, or life threatening diseases~* Presence of any other chronic neuropathic pain states~* History of seizure~* Pending litigation~* Lack of ability to understand the experimental protocol and to adequately communicate in English~* History of chronic headache prior to the incidence of MTBI

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Transcranial Magnetic Stimulation (Type: EXPERIMENTAL): Active-repetitive transcranial magnetic stimulation (rTMS) at the dorsal lateral prefrontal cortex.
- Sham Transcranial Magnetic Stimulation (Type: SHAM_COMPARATOR): Sham rTMS will consist of the same parameters as active, however, the subject will be shielded from the magnetic field of the coil.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Type 1 diabetes for at least one year~* HbA1c 7-11% (both inclusive)~* Treated with insulin for at least six months - any regimen~Exclusion Criteria:~* Any systemic treatment with products which in the Investigator's opinion could interfere with glucose or lipid metabolism (eg systemic corticosteroids) 3 months prior to randomisation~* Subject has a clinically significant, active (during the past 12 months) disease of the gastrointestinal, pulmonary, neurological, genitourinary, or haematological system that, in the opinion of the Investigator, may confound the results of the trial or pose additional risk in administering trial product

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- SIBA (D) (Type: EXPERIMENTAL): None
- SIBA (E) (Type: EXPERIMENTAL): None
- IGlar (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Use of Focalin for Fatigue in Sarcoidosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of sarcoidosis using standard criteria~* Disease for more than one year~* Complain of fatigue which has been present for more than six months.~* Over 18 years of age~Exclusion Criteria:~* Pregnancy~* Change in therapy for sarcoidosis in prior three months~* history of ventricular arrythmias~* Patients with a history of anxiety disorder, glaucoma, motor ties or a family history of Tourette's syndrome.~* Patients who are currently receiving or have received monoamine oxidase inhibitors within 14 days prior to study entry.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Leukotriene Receptor Antagonist Montelukast in the Treatment of Non-alcoholic Steatohepatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- The inclusion criteria were adult patients (age \>18 years old) of both sexes, overweight/obese subjects with presence of evidence of hepatic steatosis by imaging (increased liver echogenicity, stronger echoes in the hepatic parenchyma, vessel blurring, and narrowing of the lumen of the hepatic veins). Patients with mild to moderate elevation in aminotransferase activities (\> 2 but \<5 times upper limit of normal), hepatic steatosis index (HIS) \>36, Fibro-scan score \>7 kpa and \<12.5 kpa (F0-F3), and HAIR score of 2 or 3 were included in the study.~Exclusion Criteria:~- The exclusion criteria included smokers, patients with secondary hepatic fat accumulation which results from using steatogenic medications or hereditary disorders. Alcohol consumers, patients with Wilson's disease, hemochromatosis, viral hepatitis, decompensated liver disease, inflammatory diseases, diabetes, depression and patients with other comorbid conditions that elevate transaminases (congestive heart failure and malignancy) pregnancy and lactating women were excluded

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Control group (Type: PLACEBO_COMPARATOR): 26 patients will receive placebo (Control group)
- Montelukast group (Type: EXPERIMENTAL): 26 patients will receive montelukast 10 mg/ day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete